CUPR Cuprina Holdings (Cayman) LTD Annual reports only
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1995704 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY9.2%
TTM net income YoY-216.7%
TTM EPS YoY-178.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-1.3%
Operating margin-9,680.1%
Net margin-9,366.7%
FCF margin-18,423.3%
EBITDA margin-9,606.9%
Returns
ROE-1,115.0%
ROA-92.0%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets40.6%
Debt / equity0.03x
Current ratio2.35x
Interest coverage-328.02x
Cash quality & payout
Operating cash flow / net income1.95x
Accruals ratio87.9%
Payout ratio—
Capex / revenue116.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $38,789 | $35,522 |
| Cost of revenue | $39,290 | $37,745 |
| Gross profit | -$501 | -$2,223 |
| R&D expense | $176,385 | $177,433 |
| SG&A expense | $3.58M | $1.03M |
| Operating income | -$3.75M | -$1.21M |
| Interest expense | $11,447 | $1,311 |
| Pretax income | -$3.58M | -$1.11M |
| Net income | -$3.63M | -$1.15M |
| EBITDA | -$3.73M | -$1.18M |
| EPS (basic) | -17.75 | -6.38 |
| EPS (diluted) | -17.75 | -6.38 |
| Weighted avg. shares (diluted) | 20.47M | 18.00M |
| Banking | ||
| Net interest income | -$11,447 | -$27,354 |
| Provision for credit losses | -$2,960 | -$1,553 |
| Balance sheet | ||
| Cash & equivalents | $2.42M | $85,622 |
| Receivables | $14,163 | $19,399 |
| Inventory | — | $1,272 |
| Current assets | $5.70M | $1.22M |
| PP&E, net | $60,270 | $42,685 |
| Total assets | $6.61M | $1.28M |
| Current liabilities | $2.42M | $4.44M |
| Short-term debt | $30,108 | $40,616 |
| Long-term debt | $98,112 | $120,362 |
| Total debt | $128,220 | $160,978 |
| Total liabilities | $2.68M | $4.56M |
| Shareholders' equity | $3.93M | -$3.28M |
| Net debt | -$2.30M | $75,356 |
| Cash flow statement | ||
| Operating cash flow | -$7.10M | -$908,609 |
| Capital expenditure | $45,268 | $16,088 |
| Free cash flow | -$7.15M | -$924,697 |
| Investing cash flow | -$45,268 | -$16,088 |
| Financing cash flow | $9.51M | $985,795 |
| Depreciation & amortization | $28,394 | $31,012 |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.